<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03523039</url>
  </required_header>
  <id_info>
    <org_study_id>ID 2018-00421</org_study_id>
    <nct_id>NCT03523039</nct_id>
  </id_info>
  <brief_title>Hemoadsorption With CytoSorb® in Post-Cardiac Arrest Syndrome</brief_title>
  <acronym>CATCH</acronym>
  <official_title>Hemoadsorption With CytoSorb® in Post-Cardiac Arrest Syndrome: a Pilot Study (The CATCH Trial: Post Cardiac Arrest Therapy With Cytosorb Hemoadsorption)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective single-centre randomized control trial aims at evaluating the safety and
      efficacy of hemoadsorption with CytoSorb® in 40 patients with Post-Cardiac Arrest Syndrome
      admitted to the ICU.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients presenting Post-Cardiac Arrest Syndrome (PCAS) in the 24 hours following their
      admission in Intensive Care Unit will be randomly assigned either to a control group
      (standard of care) either to a &quot;Hemoadsorption&quot; group. In the latter, the patient will be
      connected in the 6 hours following randomization to an extracorporeal circuit, in which a
      Cytosorb ® cartridge will be placed. The circuit will be set up in hemoperfusion mode. The
      therapy will take place for a minimum of 12 hours and a maximum of 24 hours. Anticoagulation
      will be achieved using a regional heparin-protamin regimen.

      Blood samples will be collected at randomization, T1 (6 hours post-randomization), T2 (12
      hours after randomization), T3 (24 hours after randomization), T4 (48 hours after
      randomization) and T5 (48 hours after randomization), to assess change in inflammatory
      cytokine levels.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cytokine levels</measure>
    <time_frame>From baseline (randomization) to 72 hours after randomization</time_frame>
    <description>Plasma levels reduction of the following inflammatory mediators: IL-1β,IL-1Ra, IL-6, IL-8, IL-10 and TNF-α.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>From beginning of hemoadsorption to 24 hours after the end of hemoadsorption, incidence of adverse events such as haemorrhagic complications, catheter-insertion related complications and anaphylactoid reactions</time_frame>
    <description>Rate of intervention-related complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vasopressor requirements</measure>
    <time_frame>From baseline (randomization) to 72 hours after randomization</time_frame>
    <description>Including the number of patients with a 50% decrease in the baseline vasopressor dose after 6, 12, 24, 36 and 48 hours, and the % of patients requiring a vasopressor dose increase within 24 hours of baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>Day 14, 28 and 90 after randomization</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shock reversal</measure>
    <time_frame>Within 24 hours from randomization</time_frame>
    <description>Percentage of patients with shock reversal shock reversal being defined in the present study as a norepinephrine dose &lt;0.1μg/kg/min to maintain MAP &gt;60-70 mmHg and a serum lactate level ≤2 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment Score (SOFA)</measure>
    <time_frame>Day 1 to 7 after randomization</time_frame>
    <description>Total Daily SOFA Score. The score ranges from 0 (best outcome) to 24 (worst outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP and Procalcitonin Levels</measure>
    <time_frame>Day 1, 2, 3 after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>Hemoadsorption</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemoadsorption is performed using a CytoSorb® cartridge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Post-cardiac arrest management will be conducted as per institutional protocols.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CytoSorb® Hemoadsorption</intervention_name>
    <description>The therapy is initiated within 6 hours from randomization and maintained for a minimum of 12 consecutive hours to a maximum of 24 consecutive hours.</description>
    <arm_group_label>Hemoadsorption</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Norepinephrine dose &gt; 0.2 µg/kg/min to maintain Mean Arterial Pressure &gt; 60-70 mmHg,
             for at least one hour

          -  Need of any other vasoactive agent (including epinephrine and/or dobutamine)

        Exclusion Criteria:

          -  Evidence for patient's refusal to participate in clinical trials

          -  Non commitment for ongoing medical therapy (imminent withdrawal of care)

          -  Non-cardiac causes of CA likely (asphyxia, drowning, hypoxia)

          -  Cardiac arrest caused by hemorrhagic shock

          -  Contraindications to therapeutic heparinization

          -  Shock of primary cardiac origin (LVEF &lt;20%)

          -  Platelet count &lt;20 G/L

          -  Deep immunosuppression state, as defined by neutrophils &lt;1 G/L or CD4 &lt;200 /mm3

          -  Pregnancy

          -  Acute sickle cell crisis

          -  Refractory cardiac arrest with ECMO implantation

          -  Need for renal replacement therapy at time of randomization

          -  Concomitant enrolment in another study

          -  Non availability of the research team at time of eligibility at time of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Schneider, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine Schneider, MD, PhD</last_name>
    <phone>+41795561902</phone>
    <email>antoine.scheider@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mauro Oddo, MD, PD</last_name>
    <phone>+4121 314 39 23</phone>
    <email>mauro.oddo@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine Schneider, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>May 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Antoine Schneider</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Cardiac Arrest</keyword>
  <keyword>Cytokine Hemoadsorption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

